Remote SIM provisioning is a vital enabler for machine-to-machine (M2M) and Internet of Things (IoT) technology, providing a simplified, secure and seamless mobile connection for all types of connected machines and devices. The benefits are multi-dimensional and touch every aspect of the product lifecycle, from manufacturing all the way through to user experience.
Based on the GSMA Remote Provisioning Architecture for embedded universal integrated circuit cards (eUICC), the Arkessa reprogrammable SIM solution is transforming the way original equipment manufacturers (OEMs) design and deploy enterprise-grade IoT solutions. OEMs can now build global connectivity into their products for a superior user experience usually only seen with premium smartphone or e-reader devices. Of course, IoT devices do not typically have screens or user-operators, which makes the network services themselves the critical components in delivering a zero-touch provisioning and operational experience.
Arguably one of the most compelling connected health products to launch in 2018 is Actiste, a mobile health solution that simplifies insulintreated diabetes by gathering and sharing personal health data between patients and healthcare professionals through a connected pocket-sized device.
Actiste, developed by Brighter AB, will be marketed and sold as a service to both consumers and the healthcare sector across the globe. The flexibility offered by eUICC is key to simplifying the go-to-market process and the customer experience by ensuring out-of-the-box connectivity, but also in localising that connectivity.
Brighter’s vision is that patients get the best possible user experience. From a connectivity point of view, this means that cellular connectivity works without intervention from the user, meaning zero-touch connectivity without the need for pairing to Wi-Fi or Bluetooth. It also means no bill shock due to unintended roaming. Data security under the General Data Protection Regulation (GDPR) is another critical dimension for Actiste users and data localisation is a key element in addressing that.
As an eUICC-enabled device, the network connectivity services for Actiste can be managed remotely and automatically via Arkessa’s MVNO services, incorporating Ericsson’s Device Connection Platform (DCP) and the Gemalto On Demand Connectivity (ODC) solution. These remote management services allow Brighter to localise or customise the connectivity services according to local regulations and geographic and commercial requirements once Actiste is in the field.
Sweden-based company Brighter was launched in order to provide services and solutions that facilitate self-care and self-monitoring for patients to help them manage their diabetes better. Actiste is its first mobile health product.
More than 422 million people suffer from diabetes. By 2040 this number is expected to rise to 642 million, according to the World Health Organisation’s Global Report on Diabetes, 2014. These figures equate to approximately 8.5% of the world’s adult population, and trends show that this number is rising, as lifestyles grow ever more sedentary and obesity and inactivity continue to cause problems for health services across the globe.
Living with insulin-treated diabetes can be challenging. Complications arising from an imbalance of insulin in the body can mean illness and discomfort for patients, and costs of millions of euros for health services.
Of course, giving patients the tools they need to manage their diabetes accurately and reliably doesn’t mean that health professionals are no longer monitoring patients. In fact, Brighter makes it easier for doctors and nurses to monitor their patients as data is collected more accurately and consistently. Information about a patient’s insulin levels and general health is stored and delivered through a cloud-based platform, and patients can choose to share real-time data with their caregivers for ongoing monitoring purposes, or even for access in an emergency.
By gathering personal health data from diabetes patients and sharing it with their caregivers, Brighter’s Actiste enables patients to better manage their condition, and lets caregivers monitor and personalise treatment more accurately. Patients and caregivers can track sugar levels and insulin dosages using a dedicated app, and the device administers the correct levels of insulin required whilst keeping track of exactly how much insulin a patient has injected.
Unlike anything else on the market today, Actiste facilitates measurement of glucose levels, prescriptive insulin injections, and automatic logging and timing of all activity within a single unit, making life better for people with diabetes.
Living with a condition like diabetes can sometimes make it harder to experience life to the full. Going on holiday abroad, for example, can be a challenge for people with diabetes. Globally connected eUICC technology within the Actiste device means that patients can travel, reassured that they can keep their diabetes accurately under control, and that Actiste can help them stay in touch with their caregiver back home.
The assured connectivity provided by eUICC is based on its ability to host multiple SIM profiles. The built-in global roaming profile for default and backup connectivity and a profile switching service for applying local mobile network operator profiles allow OEMs and service providers to focus on what they do best – for Brighter this is the provision of mobile healthcare that positively influences patient behaviour and improves the lifestyle for people suffering from chronic illness. Arkessa is extremely proud to provide mobile connectivity services for Actiste and looks forward to seeing it fulfil its worldchanging potential.
Read more about eUICC at www.arkessa.com/euicc
